Generic drugs

Lilly loses patent dispute over Alimta in London court

May 15, 2014
Bloomberg News
Eli Lilly and Co. lost a United Kingdom lawsuit over its Alimta cancer treatment when a judge ruled Thursday that a generic version planned by Actavis Plc doesn't breach European patents.
More

Drug prices surge as generics, niche treatments eat profit

May 1, 2014
Bloomberg News
Since 2007, the cost of brand-name medicines has jumped, with prices doubling for dozens of established drugs that target everything from multiple sclerosis to cancer, blood pressure and even erections, according to an analysis conducted for Bloomberg News.
More

Lilly forecasts sales, profit drop in face of rival generic drugs

January 7, 2014
Bloomberg News
In a warning shot to investors, the pharmaceutical giant says it expects "2014 to be the most financially challenging year of Lilly’s current period of patent expirations."
More

Pfizer, Teva reach deal to allow generic Viagra

December 18, 2013
Bloomberg News
Fifteen years after Pfizer Inc.’s Viagra changed the sexual equation for older men, the blockbuster impotence drug is set to become available in a less expensive generic form as early as 2017.
More

FDA approves first generic versions of Lilly's Cymbalta

December 11, 2013
Associated Press
Cymbalta is Eli Lilly and Co. Inc.'s best-selling drug and posted 2012 sales of $4.7 billion, making it the fifth-highest selling medication in the world. The drug's patent expired Wednesday.
More

Bribery scandals sap Lilly’s China growth

October 28, 2013
J.K. Wall
Eli Lilly and Co. has been counting on torrid growth in China to help offset losses from patent expirations in other markets, but now slower growth in the Chinese economy and bribery allegations against Lilly and two other drugmakers have hampered Lilly’s growth there.
More

Drugmakers may face ‘pay for delay’ suits, high court rules

June 18, 2013
Bloomberg News
Drug companies like Eli Lilly and Co. can be sued for paying rivals to delay low-cost versions of popular medicines, the U.S. Supreme Court said in a decision that rewrites the rules governing the release of generic drugs.
More

Court may decide if drugmakers can pay to delay generics

March 25, 2013
Associated Press
Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for years, steep price declines.
More

Profits at center of biosimilars debate

March 18, 2013
J.K. Wall
House Bill 1315, which is scheduled for a Senate floor hearing on Monday, would require pharmacists to check with a patient’s physician before automatically substituting a generic version of a biotech drug for a brand-name version.
More

Lilly sinks $20M into Chinese firm for 'branded generic' drugs

June 12, 2012
J.K. Wall
Eli Lilly and Co. has invested $20 million in Chinese pharmaceutical company Novast Labs in an effort to build up a portfolio of branded generic medicines in the fast-growing Asian market.
More

Lilly unlikely to gain from Plavix patent loss, analyst says

May 17, 2012
Bloomberg News
Indianapolis-based Eli Lilly and Co. and London-based AstraZeneca Plc aren't expected to have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co.’s Plavix after the drug loses U.S. patent protection Thursday.
More

WellPoint won’t put brand-name Lipitor on generics list

December 1, 2011
Bloomberg News
Indianapolis-based WellPoint Inc., the largest U.S. health insurer by enrollment, will favor a copy of the blockbuster cholesterol medication made by Watson Pharmaceuticals Inc., the insurer said.
More

Zyprexa era comes to an end for LillyRestricted Content

October 27, 2011
 IBJ Staff
On Oct. 24, the U.S. Food and Drug Administration approved the first generic versions of Eli Lilly and Co.’s best-seller, ending 15 years of highly lucrative sales.
More

FDA approves first generic versions of Zyprexa

October 24, 2011
 IBJ Staff and Associated Press
Federal health officials on Monday approved the first generic versions of the blockbuster drug Zyprexa, which posted sales of $5.7 billion last year for Indianapolis-based drugmaker Eli Lilly and Co Inc.
More

Lilly: Vendors key after Zyprexa patent loss

October 24, 2011
J.K. Wall
Lilly's patent-loss challenges—the biggest of which takes effect today—will force the company to rely even more on its 1,300 Indiana vendors.
More

Eli Lilly's Elanco unit blossoming at just the right timeRestricted Content

July 30, 2011
Greg Andrews
An investment firm projects that the Elanco animal-health business will generate sales of nearly $2 billion by 2012 and surpass $3 billion by 2018.
More

Lilly wins appeals court ruling in Strattera patent case

July 29, 2011
Bloomberg News
The U.S. Court of Appeals for the Federal Circuit in Washington, D.C., overturned Friday a judge’s decision that Lilly’s patent on attention-deficit treatment Strattera was invalid.
More

Lilly asks judge to reject U.K. Zyprexa case

July 5, 2011
Bloomberg News
Eli Lilly and Co., the Indianapolis-based drugmaker whose best-selling schizophrenia medicine Zyprexa survived a patent challenge in Britain two years ago, has asked a United Kingdom judge to reject a parallel lawsuit by a generic drug company.
More

Lilly plans 10 drugs in final-stage trials by year's end

June 30, 2011
Bloomberg News
Lilly has 33 drugs in the second and third stages of clinical trials, including medicines for cancer, diabetes and Alzheimer’s disease, up from seven in 2005, the Indianapolis-based company said Thursday.
More

Drug industry outlook negative through 2012, Moody’s says

June 8, 2011
Bloomberg News
Earnings growth will continue to slow in 2011 for most of the industry’s biggest companies, analyst predicts.
More

Growth in drug spending to slow as generics rise

May 18, 2011
Bloomberg News
The annual growth rate in spending on drugs may be cut in half over the next five years as people opt for less expensive generic medicines over brand-name treatments, a health-care research group said Wednesday, highlighting the challenge pharmaceutical firms like Eli Lilly and Co. are facing.
More

Two wins to bring Lilly modest sales

May 9, 2011
J.K. Wall
Finally, some new revenue. Eli Lilly and Co. will enjoy modest new sales later this year after U.S. regulators approved a new diabetes drug developed by a partner company, and another company nears approval on a drug that will produce royalties for the Indianapolis-based drugmaker.
More

Trade agency to probe Lilly's infringement claim

March 17, 2011
Bloomberg News
Eli Lilly and Co.’s patent-infringement claim over Hospira Inc.’s generic version of the cancer treatment Gemzar will be investigated by a U.S. trade agency with the power to block imports of the copycat drug.
More

Lechleiter: After the deluge, we'll be fine

March 16, 2011
J.K. Wall
Eli Lilly and Co. CEO John Lechleiter visited Japan last week—three days before the massive earthquake—to deliver his tried-and-true message: Drug companies need to reinvent invention, governments needs to support innovation, and Lilly will be just fine after it has sustained the damage of the next three years.
More

Recent successes don't change Lilly's outlook

February 9, 2011
J.K. Wall
Eli Lilly and Co. can be credited with using acquisitions to unclog its product pipeline. It launched two drugs in the past 18 months, won market approval for a third and will likely get nods for two more drugs this year. Trouble is, they all have paltry sales prospects.
More
Page  1 2 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. So much for Eric Holder's conversation about race. If white people have got something to say, they get sued over it. Bottom line: white people have un-freer speech than others as a consequence of the misnamed "Civil rights laws."

  2. I agree, having seen three shows, that I was less than wowed. Disappointing!!

  3. Start drilling, start fracking, and start using our own energy. Other states have enriched their citizens and nearly elminated unemployment by using these resources that are on private land. If you are against the 'low prices' of discount stores, the best way to allow shoppers more choice is to empower them with better earnings. NOT through manipulated gov mandated min wage hikes, but better jobs and higher competitive pay. This would be direct result of using our own energy resources, yet Obama knows that Americans who arent dependent of gov welfare are much less likely to vote Dem, so he looks for ways to ensure America's decline and keep its citizens dependent of gov.

  4. Say It Loud, I'm Black and Ashamed: It's too bad that with certain "black" entertainment events, it seems violence and thuggery follows and the collateral damage that it leaves behinds continues to be a strain on the city in terms of people getting hurt, killed or becoming victims of crimes and/or stretching city resources. I remember shopping in the Meadows area years ago until violence and crime ended make most of the business pack you and leave as did with Lafayette Square and Washington Square. Over the past 10 to 12 years, I remember going to the Indiana Black Expo Soul Picnic in Washington Park. Violence, gang fights and homicides ended that. My great grandmother still bears the scares on her leg from when she was trampled by a group of thugs running from gun fire from a rival gang. With hundreds of police offices downtown still multiple shootings, people getting shot downtown during Black Expo. A number of people getting shots or murdered at black clubs around the city like Club Six on the west side, The Industry downtown, Jamal Tinsley's shot out in front of the Conrad, multiple fights and shootings at the skating rinks, shootings at Circle Center Mall and shooting and robberies and car jackings at Lafayette Mall. Shootings and gang violence and the State Fair. I can go on and on and on. Now Broad Ripple. (Shaking head side to side) Say It Loud, I'm Black and I'm Ashamed.

  5. Ballard Administration. Too funny. This is the least fiscally responsive administration I have ever seen. One thing this article failed to mention, is that the Hoosier State line delivers rail cars to the Amtrak Beech Grove maintenance facility for refurbishment. That's an economic development issue. And the jobs there are high-paying. That alone is worth the City's investment.

ADVERTISEMENT